Progression of disease and a remedy: Causative role of macrophages and microglia: Remedial effect of immunomodulatory and immunosuppressive therapies "in combination"

Medical Hypotheses

Volumn 67, Issue 4, 2006, Pages 736-739

  Milder, Dan G ^a,b  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b BANKSTOWN LIDCOMBE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; ANTIGEN PRESENTING CELL; ARTICLE; CELL ACTIVATION; DIABETES MELLITUS; DISEASE COURSE; DOWN REGULATION; HUMAN; IMMUNOGLOBULIN PRODUCTION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MACROPHAGE; MICROGLIA; MULTIPLE SCLEROSIS; PARKINSON DISEASE; PRIORITY JOURNAL; RETINA MACULA DEGENERATION;

ANTIGEN-PRESENTING CELLS; COMPLEMENT SYSTEM PROTEINS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOGLOBULINS; IMMUNOSUPPRESSIVE AGENTS; MACROPHAGE ACTIVATION; MACROPHAGES; MICROGLIA; MODELS, IMMUNOLOGICAL;

EID: 33745946858     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2006.06.001     Document Type: Article

References (24)

1. Milder D.G. On the nature of degenerative diseases and possible therapy: a hypothesis. Acta Myologica 23 (2004) 103-105
2. Milder D.G. Therapeutic, pathogenetic and nosologic aspects of multiple sclerosis: relevance to the degenerative diseases. In: Columbus F. (Ed). Progress in multiple sclerosis research (2005), Nova Scientific Press, New York 113-137
3. Milder D.G. Partial and significant reversal of progressive visual and neurologic deficits in multiple sclerosis: a possible therapeutic effect. Clin Exp Ophthalmol 30 (2002) 363-366
4. Milder D.G. Immunomodulatory therapies and low dose Azathioprine reverse partially and significantly progressive visual and neurologic deficits in multiple sclerosis: further observations. Acta Myologica 21 (2002) 144-150
5. Prineas J.W., Kwon E.E., Cho E.S., et al. Immunopathology of secondary-progressive multiple sclerosis. Ann Neurol 50 (2001) 646-657
6. Yoon J.W., Jun H.S., and Santamaria P. Cellular and molecular mechanisms for the initiation and progression of beta cell destruction resulting from the collaboration between macrophages and T cells. Autoimmunity 27 (1998) 109-122
7. Kumar V., Ali S.R., Konrad S., Zwirner J., Verbeek S., Schmidt R., et al. Cell-derived anaphylatoxins as key mediators of antibody-dependent type II autoimmunity in mice. J Clin Invest 116 (2006) 512-520
8. Gewurz H., Zhang X.H., and Lint T.F. Structure and function of the pentraxins. Curr Opin Immunol 7 (1995) 54-64
9. Molina H., Holer V.M., Li B., Fung Y., Mariathasan S., Goellner J., et al. Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. Proc Natl Acad Sci USA 93 (1996) 3357-3361
10. Muller-Eberhard H.J. Molecular organization and function of the complement system. Ann Rev Biochem 57 (1988) 321-347
11. Hussien Y., Sanna A., Soderstrom M., et al. Glatiramer acetate and IFN-beta act on dendritic cells in multiple sclerosis. J Neuroimmunol 121 (2001) 102-110
12. Fridkis-Hareli M., Teitelbaum D., Gurevich E., Pecht I., Brautbar C., Kwon O.J., et al. Direct binding of myelin basic protein and synthetic copolymer 1 to class 2 major histocompatibility complex molecules on living antigen-presenting cells - specificity and promiscuity. Proc Natl Acad Sci USA 1 (1994) 4872-4876
13. Le W., Rowe D., Xie W., Ortiz I., He Y., and Appel S.H. Microglial activation and dopaminergic cell injury: an in vitro model relevant to Parkinson's disease. J Neurosci 21 (2001) 8447-8455
14. He Y., Le W.D., and Appel S.H. Role of Fc gamma receptors in nigral cell injury induced by Parkinson disease immunoglobulin injection into mouse substantia nigra. Exp Neurol 176 (2002) 322-327
15. Mohamed H.A., Mosier D.R., Zou L.L., et al. Immunoglobulin Fc gamma receptor promotes immunoglobulin uptake, immunoglobulin-mediated calcium increase, and neurotransmitter release in motor neurons. J Neurosci Res 69 (2002) 110-116
16. Fearon D.T., and Locksley R.M. The instructive role of innate immunity in the acquired immune response. Science 272 (1996) 50-53
17. Klein R.J., Zeiss C., Chew E.Y., Tsai Y.J., Sackler R.S., Haynes C., et al. Complement factor H polymorphism in age-related macular degeneration. Science 308 (2005) 385-389
18. McDowell J.V., Tran E., Hamilton D., Wolfgang J., Miller K., and Marconi R.T. Analysis of the ability of Spirochete species associated with relapsing fever, avian Borreliosis, and epizootic bovine abortion to bind factor H and cleave C3b. J Clin Microbiol 41 (2003) 3905-3910
19. Engel A.G., Lambert E.H., and Howard F.M. Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis. Ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin Proc 52 (1977) 267-280
20. Simon D., Seznec H., Gansmuller A., Carelle N., Weber P., Metzger D., et al. Friedreich ataxia mouse models with progressive cerebellar and sensory ataxia reveal autophagic neurodegeneration in dorsal root ganglia. J Neurosci 24 (2004) 1987-1995
21. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 340 (1999) 115-126
22. Yasojima K., Schwab C., McGeer E.G., and McGeer P.L. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 158 (2001) 1039-1051
23. Yuan L., and Neufeld A.H. Activated microglia in the human glaucomatous optic nerve head. J Neurosci Res 64 (2001) 523-532
24. Chen J.J., Yao P.L., Yuan A., Hong T.M., Shun C.T., Kum M.L., et al. Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin Cancer Res 9 (2003) 729-737